EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data

Jens Panse iD, Koo Wilson, Jesse Fishman, Piotr Wojciechowski, Marlena Wdowiak, Regina Horneff, Christopher J Patriquin, Monika Oliver, Zalmai Hakimi

European Journal of Haematology · 2023

DOI: 10.1111/ejh.13969 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Jens Panse und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, non‐malignant haematological disorder associated with disabling fatigue and reduced health‐related quality of life. Post hoc analysis of PEGASUS phase 3 trial (NCT03500549) characterised improvements in patient‐reported fatigue measured by functional assessment of chronic illness therapy‐fatigue (FACIT‐fatigue) instrument item‐level ratings for pegcetacoplan and eculizumab for the treatment of PNH.

Methods

Item‐level responder analysis was conducted on a ≥2‐level change from baseline (CFB) clinically important response (CIR) for the FACIT‐fatigue 13 individual items rated on a 5‐level Likert scale. We evaluated ≥2‐level change against the minimal clinically important difference (MCID) of the FACIT‐fatigue total score (≥5 points) and clinical parameters, haemoglobin (Hb; ≥1 g/dL) and normalised absolute reticulocyte count (ARC; 30–100 pg/cells). Logistic regressions estimated baseline‐to‐Week‐16 FACIT‐fatigue item‐level transitional probabilities; Kaplan–Meier analysis estimated time to FACIT‐fatigue item CIR.

Results

Pegcetacoplan versus eculizumab was associated with significantly greater odds of Week 16 CIR across 8/13 items and on total score MCID (OR [CI] = 11.19 [3.73, 33.57]) and faster times to responses. The item‐level CIR threshold also showed clinical relevance on Hb level and ARC normalization.

Conclusions

Compared with eculizumab, pegcetacoplan was associated with clinically meaningful greater improvements on a majority of FACIT‐fatigue items.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansFatigueHemoglobinsQuality of LifePeptides, Cyclic

Stichwörter der Autor:innen

FACIT-fatiguePEGASUSfunctional assessment of chronic illness therapy-fatiguehealth related quality of lifeparoxysmal nocturnal haemoglobinuria

Substanzen

HemoglobinspegcetacoplanPeptides, Cyclic

Autor:innen und Institutionen

  • Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
  • Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf (CIO ABCD), Aachen, Germany.
  • Swedish Orphan Biovitrum AB, Stockholm, Sweden.
  • Apellis Pharmaceuticals, Inc., Waltham, Massachusetts, USA.
  • Assignity Sp. z O.O., Krakow, Poland.
  • Putnam Associates, Krakow, Poland.

ORCID-Profile: Jens Panse

Förderung

  • Swedish Orphan Biovitrum

Zitieren

APA

Panse, J., Wilson, K., Fishman, J., Wojciechowski, P., Wdowiak, M., Horneff, R., Patriquin, C. J., Oliver, M., & Hakimi, Z. (2023). Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. European Journal of Haematology. https://doi.org/10.1111/ejh.13969

Vancouver

Panse J, Wilson K, Fishman J, Wojciechowski P, Wdowiak M, Horneff R, et al. Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. European Journal of Haematology. 2023. doi:10.1111/ejh.13969

BibTeX
@article{Panse2023,
  author = {Panse, Jens and Wilson, Koo and Fishman, Jesse and Wojciechowski, Piotr and Wdowiak, Marlena and Horneff, Regina and Patriquin, Christopher J and Oliver, Monika and Hakimi, Zalmai},
  title = {Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.13969}
}
Kostenlos starten →